

In the claims:

1. (original) A method for treating cancer in a mammal in need thereof which comprises administering to said mammal amounts of a selective inhibitor of the activity of one or more of the isoforms of Akt.

2. (original) The method according to Claim 1 wherein the selective inhibitor is a small organic molecule.

3. (original) The method according to Claim 1 wherein the selective inhibitor inhibits the phosphorylation of one or more of the isoforms of Akt by upstream kinases and inhibits the phosphorylation of protein targets of an isoform or isoforms of Akt by the activated isoform or isoforms of Akt.

4. (original) The method according to Claim 1 wherein the selective inhibitor inhibits the phosphorylation of one or more of the isoforms of Akt by upstream kinases or inhibits the phosphorylation of protein targets of an isoform or isoforms of Akt by the activated isoform or isoforms of Akt.

5-6. (canceled).

7. (original) The method according to Claim 1 wherein the inhibitor is a selective inhibitor of the activity of Akt1 and Akt2.

8-10. (canceled).

11. (original) A method for treating cancer in a mammal in need thereof which comprises administering to said mammal amounts of an inhibitor of the activity of one or more of the isoforms of Akt wherein the inhibition by the inhibitor is dependent on the presence of the pleckstrin homology domain of the isoforms of Akt.

12-14. (canceled).

15. (original) The method according to Claim 11 wherein the inhibitor is a selective inhibitor of Akt1 and Akt2.

16.-37. (canceled).

38. (original) The method according to Claim 1 wherein the inhibitor is a selective inhibitor of the activity of Akt1 and Akt2, but is not an inhibitor of the activity of a modified Akt1 that lacks the pleckstrin homology domain, a modified Akt2 that lacks the pleckstrin homology domain or both a modified Akt1 and a modified Akt2 protein that lack their pleckstrin homology domains.

39.-55. (canceled).